Please use this identifier to cite or link to this item:
|dc.title||Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726|
|dc.identifier.citation||Seah, Q.M.,New, L.-S.,Chan, E.C.Y.,Boelsterli, U.A. (2008-08). Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726. Drug Metabolism Letters 2 (3) : 153-157. ScholarBank@NUS Repository. <a href="https://doi.org/10.2174/187231208785425791" target="_blank">https://doi.org/10.2174/187231208785425791</a>|
|dc.description.abstract||We used immortalized human hepatocytes to study the bioactivation of leflunomide and the metabolic degradation to its major metabolite, A77 1726. Both leflunomide and A77 1726 caused a time- and concentration-dependent increase in LDH release. The cytotoxicity of leflunomide, but not that of A77 1726, was prevented by the pan-CYP inhibitor, 1-aminobenzotriazole, indicating that an oxidative metabolite(s) was responsible for the cell Injury. LC/MS/MS analysis revealed that leflunomide was rapidly degraded in hepatocytes biphasically (t12a = 1.5 h, t1/2 b >24 h), but much slower in cell-free medium (t1/2 >24 h). In contrast, the generation of A77 1726 occurred at a similar rate in cells and cell-free systems. In conclusion, leflunomide was rapidly metabolized in human hepatocytes to A77 1726, but its toxicity was dependent on other, CYP-dependent intermediates. © 2008 Bentham Science Publishers Ltd.|
|dc.description.sourcetitle||Drug Metabolism Letters|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.